Krystal Biotech, Inc. KRYS
345.82
0.86
0.25%
as of 25 Sep
- Market cap
- $10.2B
- P/E
- 41.9×
Follow KRYS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
44.94 | 33.33 | 34.82 | 25.62 |
+8 more quarters Free account |
P/S ratio |
24.92 | 18.13 | 18.34 | 13.70 | |
P/FCF ratio |
42.57 | 31.87 | 37.69 | 30.79 | |
P/Operating CF |
146.75 | 94.12 | 92.07 | 128.88 | |
P/B ratio |
8.08 | 5.93 | 5.85 | 4.49 | |
Price to Tangible BV |
8.08 | 5.93 | 5.85 | 4.49 | |
EV/Sales |
23.00 | 16.16 | 16.21 | 11.74 | |
EV/EBITDA |
49.55 | 36.37 | 37.58 | 26.58 | |
EV/Operating CF |
37.19 | 26.94 | 31.40 | 24.86 | |
EV/FCF |
39.29 | 28.40 | 33.31 | 26.38 | |
Quick Ratio |
7.73 | 8.82 | 9.28 | 9.43 | |
Current Ratio |
8.32 | 9.46 | 9.95 | 10.14 | |
Net Debt/EBITDA |
(14.10) | (14.86) | (17.98) | (17.01) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.34 | 0.33 | 0.34 | |
Operating CF/Net income |
1.37 | 1.44 | 1.51 | 0.50 | |
Capex/Depreciation |
(2.28) | (4.14) | (1.21) | (1.06) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.18% | 13.18% | 13.81% | 14.91% | |
Selling, General and Administrative Expense of Revenue |
33.43% | 35.25% | 38.70% | 38.42% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.87% | 11.70% | 12.85% | 13.45% | |
Graham Net Nets |
0.08 | 0.12 | 0.13 | 0.16 | |
Graham Number |
92.54 | 87.19 | 81.93 | 78.06 | |
Earnings Yield |
2.23% | 3.00% | 2.87% | 3.90% | |
Free Cash Flow Yield |
2.35% | 3.14% | 2.65% | 3.25% | |
Revenue per Share |
4.04 | 3.97 | 3.70 | 3.38 | |
Operating CF per Share |
2.53 | 2.74 | 2.68 | 1.37 | |
Capex per Share |
(0.12) | (0.24) | (0.07) | (0.06) | |
Free Cash Flow per Share |
2.41 | 2.50 | 2.60 | 1.31 | |
Cash per Share |
28.64 | 28.11 | 28.60 | 25.25 | |
Shareholders Equity per Share |
46.03 | 43.59 | 42.14 | 39.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
46.03 | 43.59 | 42.14 | 39.30 | |
Free Cash Flow |
71.22 | 73.23 | 75.37 | 37.96 | |
Working Capital |
932.25 | 911.94 | 921.66 | 834.38 | |
Capital Expenditures |
(3.56) | (7.15) | (2.14) | (1.70) | |
Net Current Asset Value |
918.13 | 899.50 | 910.37 | 823.43 | |
EV/EBIT |
51.22 | 37.72 | 39.11 | 27.65 | |
Capex to Sales |
0.03 | 0.06 | 0.02 | 0.02 | |
Net Profit Margin |
45.94% | 48.07% | 47.99% | 81.15% | |
Price to Operating Income |
55.50 | 42.33 | 44.24 | 32.26 | |
| Other line items | |||||
Average Receivables |
125.05 | 115.14 | 116.09 | 113.47 | |
Average Payables |
6.83 | 3.38 | 4.11 | 3.84 | |
Average Inventory |
38.30 | 36.29 | 33.49 | 28.11 | |
Average Assets |
1,319.52 | 1,235.69 | 1,194.82 | 1,111.21 | |
Average Common Equity |
1,199.89 | 1,130.70 | 1,082.97 | 1,011.86 |
Columns are period end dates